Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine)… Dec 15, 2021
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent… Dec 14, 2021
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate… Dec 8, 2021
Former Peloton Executive Vicki Reed Is Field Trip Health’s Newly Appointed Chief Growth Officer Dec 2, 2021
Delic’s ‘Family-First’ Program At Ketamine Wellness Centers Offers Support For Patients’ Families And Loved Ones Nov 24, 2021
